--- type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/40907824.md" description: "๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: $ImmunityBio(IBRX.US) ImmunityBio Reports Favorable Bladder Cancer Data at ๐€๐”๐€ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”๐Ÿ‘‰ ๐Š๐ž๐ฒ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ:โžค ๐€๐๐Š๐“๐ˆ๐•๐€ยฎ + BCG showed stronger complete response outcomes versus competitors.โžค NAI+BCG patients were ๐Ÿร— more likely to achieve complete response versus nadofaragene.โžค Median complete response duration reached ๐Ÿ๐Ÿ.๐Ÿ months versus ๐Ÿ—.๐Ÿ• months.โžค NAI+BCG reduced ๐œ๐ฒ๐ฌ๐ญ๐ž๐œ๐ญ๐จ๐ฆ๐ฒ risk by ๐Ÿ”๐ŸŽ% versus nadofaragene.โžค Compared with TAR-200, NAI+BCG showed numerically higher ๐Ÿ๐Ÿ-๐ฆ๐จ๐ง๐ญ๐ก CR rates.โžค NAI+BCG demonstrated significantly fewer ๐ญ๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ-๐ซ๐ž๐ฅ๐š๐ญ๐ž๐ adverse events than TAR-200.โžค Data presented at ๐€๐”๐€ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ” for BCG-unresponsive bladder cancer patients." datetime: "2026-05-19T11:37:19.000Z" locales: - [en](https://longbridge.com/en/topics/40907824.md) - [zh-CN](https://longbridge.com/zh-CN/topics/40907824.md) - [zh-HK](https://longbridge.com/zh-HK/topics/40907824.md) author: "[Hardik Shah](https://longbridge.com/en/profiles/27423834.md)" --- # ๐Ÿ“ข ๐‰๐”๐’๐“ ๐ˆ๐: $ImmunityBio(IBRX.US) ImmunityBiโ€ฆ ### Related Stocks - [IBRX.US](https://longbridge.com/en/quote/IBRX.US.md)